US · Healthcare

Brainstorm Cell Therapeutics Inc (BCLI)

Biotechnology

Brainstorm Cell Therapeutics Inc (BCLI) is listed on US in the Healthcare sector. Industry: Biotechnology. As of 2026-03-23, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for BCLI

P/E ratio

18.00

Brainstorm Cell Therapeutics Inc (BCLI) — FAQ

What is BCLI's P/E ratio?

The price-to-earnings (P/E) ratio for Brainstorm Cell Therapeutics Inc (BCLI) is 18.00 (data as of 2026-03-23).

Does Brainstorm Cell Therapeutics Inc pay a dividend?

Dividend yield is not available in the current snapshot for Brainstorm Cell Therapeutics Inc (BCLI). Check the MyAverix Finance app for the latest dividend data.

What sector is Brainstorm Cell Therapeutics Inc in?

Brainstorm Cell Therapeutics Inc (BCLI) is classified in the Healthcare sector (Biotechnology industry).

What exchange is BCLI listed on?

BCLI is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)